

Castle Biosciences Announces the Appointment of Bernhard E. Spiess as Chief Operating Officer

Friendswood, TX – May 9, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Bernhard E. Spiess to the newly created role of Chief Operating Officer.

Bernhard comes to Castle Biosciences with over 35 years of clinical diagnostics experience, most recently serving as Vice President of Product Management for both Clinical Chemistry and Infectious Diseases at Beckman Coulter, a global leader in clinical diagnostics. Throughout his career, Bernhard held positions of increasing responsibility in laboratory testing and management, scientific support, sales, strategic and tactical marketing, and product and business management. His primary focus over the last 20 years has been on immunoassay and molecular diagnostics.

Throughout his 23 years at Beckman Coulter, Bernhard played key leadership roles in the development and commercialization of a number of successful Beckman Coulter platforms. Previously, he also oversaw the company's genomic services and molecular diagnostics sales teams. Earlier in his career, Bernhard worked for Sanofi Diagnostics Pasteur and Abbott Diagnostics.

"We are excited to welcome Bernhard to our executive management team," said Derek Maetzold, President and CEO of Castle Biosciences. "We will be leveraging his experience in business management and development in the molecular diagnostics field as we advance our growing lineup of practice-changing tests."

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx[®]-UM; www.MyUvealMelanoma.com) and cutaneous melanoma (DecisionDx[®]-Melanoma; www.SkinMelanoma.com), with development programs in other underserved cancers. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com.

DecisionDx[®]-UM and DecisionDx[®]-Melanoma are trademarks of Castle Biosciences, Inc.

Media

BMC Communications

Brad Miles

646-513-3125

Bmiles@bmccommunications.com

Investors

James L Dunn, Jr., CFO

866-788-9007

IR@castlebiosciences.com